

**AMENDMENTS TO THE CLAIMS
PURSUANT TO REVISED 37 CFR § 1.121**

The following is a listing of claims that replaces all prior versions, and listings, of claims in the application:

1. (Currently Amended) An aptamer-toxin conjugate therapeutic agent comprising a targeting moiety conjugated to a cytotoxic moiety wherein said targeting moiety is an aptamer specific for PSMA (Prostate Specific Membrane Antigen).
2. (Cancelled)
3. (Cancelled)
4. (Currently Amended) The therapeutic agent of ~~claim 2~~ claim 1 wherein said cytotoxic moiety is ~~selected from the group consisting of a cytotoxic peptide, a cytotoxic protein, a small molecule chemotherapeutic agent, and a radioisotope therapeutic molecule.~~
5. (Withdrawn) The therapeutic agent of claim 3 wherein said cytotoxic moiety is selected from the group consisting of a cytotoxic peptide, a cytotoxic protein, a small molecule chemotherapeutic agent, and a radioisotope therapeutic molecule.
6. (Original) The therapeutic agent of claim 4, wherein said targeting moiety is conjugated to said cytotoxic moiety by a covalent bond.
7. (Withdrawn) The therapeutic agent of claim 5, wherein said targeting moiety is conjugated to said cytotoxic moiety by a covalent bond.
8. (Withdrawn) The therapeutic agent of claim 4 wherein said targeting moiety is conjugated to said cytotoxic moiety by a non-covalent bond.

9. (Withdrawn) The therapeutic agent of claim 5 wherein said targeting moiety is conjugated to said cytotoxic moiety by a non-covalent bond.
10. (Currently Amended) An aptamer-drug conjugate comprising one or more aptamers, wherein at least one aptamer is specific for a PSMA (Prostate Specific Membrane Antigen), and a drug linked by a linker and having the formula: (aptamer)_n -- linker -- (drug)_m, wherein n is between 1 and 10 and m is between 1 and 20.
11. (Cancelled)
12. (Withdrawn) The aptamer-drug conjugate of claim 10, wherein at least one of the one or more aptamers is specific for a target selected from the group consisting of PSMA, PSCA, e-selectin, an ephrin, ephB2, cripto-1, TENB2 (TEMFF2), ERBB2 receptor (HER2), MUC1, CD44v6, CD6, CD19, CD20, CD22, CD23, CD25, CD30, CD33, CD56, IL-2 receptor, HLA-DR10 β subunit, EGFRvIII, MN antigen, caveolin-1 and nucleolin the target PSMA.
13. (Original) The aptamer-drug conjugate of claim 10, wherein the drug is a cytotoxin.
14. (Currently Amended) The aptamer-drug conjugate of claim 10, wherein the drug is ~~selected from the group consisting of a calicheamicin, a maytansinoid, a vinca alkaloid, a cryptophycin, a tubulysin, dolastatin-10, dolastatin-15, auristatin E, rhizoxin, epothilone B, epithilone D, taxoids and variants thereof.~~
15. (Currently Amended) The aptamer-drug conjugate of claim 10, wherein the drug is ~~selected from the group consisting of Nac- γ -DMH, Nac- γ -NHS, maytansine, May-NHS, desacetyl vinblastine 3-carboxhydrazide (DAVCH), desacetyl vinblastine 4-O-succinate (DAVS), cryptophycin-52, and cryptophycin-52 amine (Cryp-NH₂).~~
16. (Original) The aptamer-drug conjugate of claim 10, wherein the linker comprises one or

more nucleophilic moieties, one or more electrophilic moieties or combinations thereof.

17. (Original) The aptamer-drug conjugate of claim 10, wherein the linker is selected from the group consisting of a Boc-protected amine, a Boc-protected amine on a heterobifunctional linker, a nucleophilic dendrimer, an electrophilic dendrimer and an electrophilic comb polymer.
18. (Original) The aptamer-drug conjugate of claim 10, wherein the linker is selected from the group consisting of Boc-NH₂-PEG-NHS, an erythritol dendrimer, an octa-polyethylene glycol dendrimer and comb polymer.